Holyoake T L, Jiang X, Jorgensen H G, Graham S, Alcorn M J, Laird C, Eaves A C, Eaves C J
Academic Transfusion Medicine Unit, Department of Medicine, Royal Infirmary, Glasgow, United Kingdom.
Blood. 2001 Feb 1;97(3):720-8. doi: 10.1182/blood.v97.3.720.
It was previously shown that patients with chronic myeloid leukemia (CML) have a rare but consistently detectable population of quiescent (G0) leukemic (Philadelphia chromosome-positive and BCR-ABL-positive [BCR-ABL+]) CD34+ cells. In the study described here, most such cells expressed a primitive phenotype (CD38-, CD45RA-, CD71-, and HLA-DR(lo)) and cultures of these cells containing growth factors produced ultimately larger, but initially more slowly growing clones than do cultures of initially cycling CD34+ leukemic cells. Initially quiescent leukemic cells expressing BCR-ABL proliferated in single-cell cultures in the absence of added growth factors, thereby demonstrating their ability to spontaneously exit G0 and enter a continuously cycling state. Interestingly, on isolation, few of these quiescent BCR-ABL+ cells contained either interleukin-3 (IL-3) or granulocyte colony-stimulating factor (G-CSF) transcripts, whereas both were present in most cycling BCR-ABL+ CD34+ cells. However, after 4 days of culture in the absence of added growth factors and in association with their entry into the cell cycle (as indicated by up-regulation of Ki-67 and cdc25 transcripts), IL-3 transcripts became detectable. These findings show that entry of leukemic (BCR-ABL-expressing) progenitors into a quiescent (G0) state in vivo is highest among the most primitive leukemic cell populations, associated with a down-regulation of IL-3 and G-CSF gene expression, and spontaneously reversible in association with up-regulation of IL-3 expression. These results highlight the potential physiologic relevance of quiescent CML progenitors, even in treated patients, in whom these cells would be predicted to have a proliferative advantage over their quiescent normal counterparts when cytokine concentrations are low.
先前的研究表明,慢性髓性白血病(CML)患者中有一群罕见但始终可检测到的静止(G0)白血病(费城染色体阳性且BCR-ABL阳性[BCR-ABL+])CD34+细胞。在本文所述的研究中,大多数此类细胞表达原始表型(CD38-、CD45RA-、CD71-和HLA-DR(低)),与最初处于增殖周期的CD34+白血病细胞培养物相比,这些含有生长因子的细胞培养物最终产生的克隆更大,但最初生长较慢。表达BCR-ABL的初始静止白血病细胞在无添加生长因子的单细胞培养物中增殖,从而证明它们有能力自发退出G0并进入持续增殖周期状态。有趣的是,在分离时,这些静止的BCR-ABL+细胞中很少有白细胞介素-3(IL-3)或粒细胞集落刺激因子(G-CSF)转录本,而大多数处于增殖周期的BCR-ABL+ CD34+细胞中都有这两种转录本。然而,在无添加生长因子的情况下培养4天后,随着它们进入细胞周期(如Ki-67和cdc25转录本上调所示),IL-3转录本变得可检测到。这些发现表明,白血病(表达BCR-ABL)祖细胞在体内进入静止(G0)状态在最原始的白血病细胞群体中最为常见,与IL-3和G-CSF基因表达下调相关,并且与IL-3表达上调相关时可自发逆转。这些结果突出了静止的CML祖细胞的潜在生理相关性,即使在接受治疗的患者中也是如此,在细胞因子浓度较低时,预计这些细胞比静止的正常对应细胞具有增殖优势。